Table 2.

Demographics, disease characteristics, laboratory and therapeutic data in patients with spondyloarthritis (SpA)

	Median (IQR 25%–75%)	Min	Max
Age (years)	36 (28–46)	18	50
Sex ratio	2.35
Marital status (%)
Unmarried	55
Married	41
Divorced	4
Educational attainment (%)
Primary education	17
Secondary education	64
University	19
Profession (%)
Unemployed	17
Student	11
Employed	72
Age of onset of SpA (years)	20 (18–32)	16	43
Age at diagnostic (years)	28 (22–35)	16	46
Disease duration (years)	11 (5–16)	1	32
Type of SpA (%)
Axial	58
Axial and peripheral	40
Peripheral	2
Extra-articular manifestation
Uveitis	9
Nephropathy	4
Osteoporosis	6
BASMI	1.5 (0–4)	0	7
PRO
Morning stiffness (min)	5 (0–15)	0	180
PGA	4 (3–6)	0	9
VAS axial pain	5 (3–6)	0	9
VAS peripheral pain	0 (0–0)	0	7
BAS-G	50 (30–60)	10	90
MASES	0 (0–0)	0	4
Number of tender joints	0 (0–0)	0	4
Number of swollen joints	0 (0–0)	0	0
BASDAI	2,6 (1.8–3.8)	0,2	6,5
ASDAS-CRP	2,18 (1.62-2.9)	0.32	4,3
BASFI	3 (1.5–5.1)	0,6	8,7
Lequesne AFI of the right hip	7 (5–8)	4	16
Lequesne AFI of the left hip	8 (5–10)	4	21
NSAIDs, %	91
csDMARDs, %	41
TNF inhibitors, %	38

AFI, Algo-Functional Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BAS-G, Bath Ankylosing Spondylitis Global Score; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein; csDMARDS, conventional synthetic disease-modifying antirheumatic drugs; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; Max, maximum; Min, minimum; NSAIDs, non-steroidal anti-inflammatory drugs; PGA, patient global assessment; PRO, patient-reported outcomes; TNF, tumour necrosis factor; VAS, Visual Analogue Scale.